← back to search

Jeffrey A. Engelman

Novartis (Germany) · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Recent clinical trials with selective inhibitors of the BRAF and MEK kinases have shown promising results in patients with tumors harboring BRAF V600 mutations. However, as has been observed previously with similarly successful targeted therapies, acquired resistance to these agents is an emerging problem that limits their clinical benefit. Several recent studies from our laboratory and others have investigated the causes of acquired resistance to BRAF and MEK inhibitors, and multiple resistance mechanisms have been identified. Here, we review these mechanisms and suggest that they can be broadly grouped into two main classes: ERK-dependent and ERK-independent. We also propose distinct therapeutic strategies that might be employed to overcome each class of acquired resistance.
h-index
131
citations
85,511
works
876
NIH funding
primary concept
email

Recent publications

A Legacy of Mentorship: A Tribute to Lewis Cantley.
2026cited by 0position: contributordoi
Data from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplementary Figure 5 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Table 2 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Figure S1 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplementary Table 2 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Figure 3 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Figure S8 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplementary Figure 4 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Table 1 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Figure S7 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplementary Figure 1 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Figure S5 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplementary Table 1 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Figure 5 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Figure 3 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Tables 1 - 12 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplementary Figure 2 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Figure S2 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplementary Figure 1 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Figure 4 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplementary Figure 5 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Figure S4 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplemental Figure and Table Legends from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplementary Figure 3 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Supplemental Figure S6 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplemental Figure S3 from Expressed Barcoding Enables High-Resolution Tracking of the Evolution of Drug Tolerance
2025cited by 0position: contributordoi
Supplementary Figure 2 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2025cited by 0position: contributordoi
Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer.
2024cited by 6position: contributordoi
Figure 1 from Dynamic Evolution of Fibroblasts Revealed by Single-Cell RNA Sequencing of Human Pancreatic Cancer
2024cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

Alice T. Shaw · Harvard University12 papers (2012–2017)A. John Iafrate · Harvard University9 papers (2012–2015)Mari Mino–Kenudson · Harvard University8 papers (2012–2015)Lecia V. Sequist · Harvard University8 papers (2012–2015)Elizabeth L. Lockerman · Center for Cancer Research7 papers (2014–2015)Gregory J. Riely · Weill Cornell Medicine6 papers (2012–2015)Dora Dias‐Santagata · University of Colorado Denver6 papers (2012–2015)Benjamin Solomon · Peter MacCallum Cancer Centre5 papers (2012–2014)Anthony C. Faber · KU Leuven5 papers (2012–2015)Justin F. Gainor · Harvard University5 papers (2014–2017)D. Ross Camidge · University of Colorado Anschutz Medical Campus5 papers (2012–2014)Matthew J. Niederst · Boston Biomedical (United States)5 papers (2013–2017)Ryohei Katayama · Center for Cancer Research5 papers (2012–2015)Ryan B. Corcoran · Harvard University5 papers (2012–2016)Pasi A. Jänne · Harvard University4 papers (2012–2017)Alexa B. Turke · Center for Cancer Research4 papers (2012–2016)Aaron N. Hata · Harvard University4 papers (2012–2015)Eunice L. Kwak · UCSF Helen Diller Family Comprehensive Cancer Center4 papers (2012–2015)John M. Asara · Harvard University3 papers (2012–2017)Geoffrey I. Shapiro · Harvard University3 papers (2012–2013)